Mechanisms involved in the control of extrapyramidal dysfunctions and in striatal dopamine synthesis.
D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001058:Apomorphine / Q000494:pharmacology; D001480:Basal Ganglia Diseases / Q000378:metabolism*; D003994:Bucladesine / Q000494:pharmacology; D002230:Carbidopa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002250:Carbon Radioisotopes; D003342:Corpus Striatum / Q000378:metabolism*; D003864:Depression, Chemical; D004298:Dopamine / Q000096:biosynthesis* / Q000494:pharmacology; D004359:Drug Therapy, Combination; D006220:Haloperidol / Q000494:pharmacology; D000882:Haplorhini; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011955:Receptors, Drug / Q000187:drug effects; D013268:Stimulation, Chemical; D014202:Tremor / Q000188:drug therapy
D000978:Antiparkinson Agents; D002250:Carbon Radioisotopes; D011955:Receptors, Drug; D007980:Levodopa; D003994:Bucladesine; D006220:Haloperidol; D002230:Carbidopa; D001058:Apomorphine; D004298:Dopamine